ID   GATA3_HUMAN             Reviewed;         443 AA.
AC   P23771; Q5VWG7; Q5VWG8; Q96J16;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   18-JUN-2025, entry version 232.
DE   RecName: Full=Trans-acting T-cell-specific transcription factor GATA-3;
DE   AltName: Full=GATA-binding factor 3;
GN   Name=GATA3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=2050118; DOI=10.1002/j.1460-2075.1991.tb07706.x;
RA   Joulin V., Bories D., Eleouet J.-F., Labastie M.-C., Chretien S.,
RA   Mattei M.-G., Romeo P.-H.;
RT   "A T-cell specific TCR delta DNA binding protein is a member of the human
RT   GATA family.";
RL   EMBO J. 10:1809-1816(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=1827068; DOI=10.1002/j.1460-2075.1991.tb08059.x;
RA   Ho I.-C., Vorhees P., Marin N., Oakley B.K., Tsai S.-F., Orkin S.H.,
RA   Leiden J.M.;
RT   "Human GATA-3: a lineage-restricted transcription factor that regulates the
RT   expression of the T cell receptor alpha gene.";
RL   EMBO J. 10:1187-1192(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=T-cell;
RX   PubMed=2017177; DOI=10.1128/mcb.11.5.2778-2784.1991;
RA   Ko L.J., Yamamoto M., Leonard M.W., George K.M., Ting P., Engel J.D.;
RT   "Murine and human T-lymphocyte GATA-3 factors mediate transcription through
RT   a cis-regulatory element within the human T-cell receptor delta gene
RT   enhancer.";
RL   Mol. Cell. Biol. 11:2778-2784(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1871134; DOI=10.1073/pnas.88.16.7284;
RA   Marine J., Winoto A.;
RT   "The human enhancer-binding protein Gata3 binds to several T-cell receptor
RT   regulatory elements.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7284-7288(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-242.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INVOLVEMENT IN HDR.
RX   PubMed=10935639; DOI=10.1038/35019088;
RA   Van Esch H., Groenen P., Nesbit M.A., Schuffenhauer S., Lichtner P.,
RA   Vanderlinden G., Harding B., Beetz R., Bilous R.W., Holdaway I., Shaw N.J.,
RA   Fryns J.-P., Van de Ven W., Thakker R.V., Devriendt K.;
RT   "GATA3 haplo-insufficiency causes human HDR syndrome.";
RL   Nature 406:419-422(2000).
RN   [10]
RP   INTERACTION WITH TBX21.
RX   PubMed=15662016; DOI=10.1126/science.1103336;
RA   Hwang E.S., Szabo S.J., Schwartzberg P.L., Glimcher L.H.;
RT   "T helper cell fate specified by kinase-mediated interaction of T-bet with
RT   GATA-3.";
RL   Science 307:430-433(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-162, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=23824597; DOI=10.1371/journal.pone.0066468;
RA   Sasaki T., Onodera A., Hosokawa H., Watanabe Y., Horiuchi S., Yamashita J.,
RA   Tanaka H., Ogawa Y., Suzuki Y., Nakayama T.;
RT   "Genome-wide gene expression profiling revealed a critical role for GATA3
RT   in the maintenance of the Th2 cell identity.";
RL   PLoS ONE 8:E66468-E66468(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 260-370 IN COMPLEX WITH DNA, AND
RP   GATA-TYPE ZINC FINGERS.
RX   PubMed=23142663; DOI=10.1016/j.celrep.2012.10.012;
RA   Chen Y., Bates D.L., Dey R., Chen P.H., Machado A.C., Laird-Offringa I.A.,
RA   Rohs R., Chen L.;
RT   "DNA binding by GATA transcription factor suggests mechanisms of DNA
RT   looping and long-range gene regulation.";
RL   Cell Rep. 2:1197-1206(2012).
RN   [14]
RP   VARIANT HDR ARG-274.
RX   PubMed=11389161; DOI=10.1136/jmg.38.6.374;
RA   Muroya K., Hasegawa T., Ito Y., Nagai T., Isotani H., Iwata Y.,
RA   Yamamoto K., Fujimoto S., Seishu S., Fukushima Y., Hasegawa Y., Ogata T.;
RT   "GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.";
RL   J. Med. Genet. 38:374-380(2001).
RN   [15]
RP   VARIANT LEU-366.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [16]
RP   VARIANT HDR GLN-298, AND CHARACTERIZATION OF VARIANT HDR GLN-298.
RX   PubMed=26514990; DOI=10.1186/s12902-015-0065-7;
RA   Okawa T., Yoshida M., Usui T., Kudou T., Iwasaki Y., Fukuoka K.,
RA   Takahashi N., Uehara Y., Oiso Y.;
RT   "A novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese family
RT   with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome.";
RL   BMC Endocr. Disord. 15:66-66(2015).
CC   -!- FUNCTION: Transcriptional activator which binds to the enhancer of the
CC       T-cell receptor alpha and delta genes. Binds to the consensus sequence
CC       5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process
CC       following immune and inflammatory responses. Positively regulates ASB2
CC       expression (By similarity). Coordinates macrophage transcriptional
CC       activation and UCP2-dependent metabolic reprogramming in response to
CC       IL33. Upon tissue injury, acts downstream of IL33 signaling to drive
CC       differentiation of inflammation-resolving alternatively activated
CC       macrophages. {ECO:0000250|UniProtKB:P23772,
CC       ECO:0000269|PubMed:23824597}.
CC   -!- SUBUNIT: Interacts with TBX21 ('Tyr-530' phosphorylated form).
CC       {ECO:0000269|PubMed:15662016}.
CC   -!- INTERACTION:
CC       P23771; P35609: ACTN2; NbExp=3; IntAct=EBI-6664760, EBI-77797;
CC       P23771; P28329-3: CHAT; NbExp=3; IntAct=EBI-6664760, EBI-25837549;
CC       P23771; Q96KQ7: EHMT2; NbExp=20; IntAct=EBI-6664760, EBI-744366;
CC       P23771; P22607: FGFR3; NbExp=3; IntAct=EBI-6664760, EBI-348399;
CC       P23771; Q9NP62: GCM1; NbExp=9; IntAct=EBI-6664760, EBI-21194843;
CC       P23771; O15379: HDAC3; NbExp=7; IntAct=EBI-6664760, EBI-607682;
CC       P23771; Q9UQL6: HDAC5; NbExp=4; IntAct=EBI-6664760, EBI-715576;
CC       P23771; Q16665: HIF1A; NbExp=3; IntAct=EBI-6664760, EBI-447269;
CC       P23771; P06239: LCK; NbExp=3; IntAct=EBI-6664760, EBI-1348;
CC       P23771; Q9BTC8: MTA3; NbExp=18; IntAct=EBI-6664760, EBI-2461787;
CC       P23771; P25788: PSMA3; NbExp=3; IntAct=EBI-6664760, EBI-348380;
CC       P23771; Q9UL17: TBX21; NbExp=6; IntAct=EBI-6664760, EBI-3922312;
CC       P23771-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-6672518, EBI-3867333;
CC       P23771-2; P59990: KRTAP12-1; NbExp=3; IntAct=EBI-6672518, EBI-10210845;
CC       P23771-2; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-6672518, EBI-11953846;
CC       P23771-2; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-6672518, EBI-11962084;
CC       P23771-2; Q3LI67: KRTAP6-3; NbExp=3; IntAct=EBI-6672518, EBI-22311199;
CC       P23771-2; Q58EX7: PLEKHG4; NbExp=3; IntAct=EBI-6672518, EBI-949255;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P23771-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P23771-2; Sequence=VSP_001598;
CC   -!- TISSUE SPECIFICITY: T-cells and endothelial cells.
CC   -!- DOMAIN: Binds DNA via the 2 GATA-type zinc fingers. Each zinc finger
CC       may bind either adjacent sites in a palindromic motif, or a different
CC       DNA molecule allowing looping and long-range gene regulation.
CC   -!- DOMAIN: The YxKxHxxxRP motif is critical for DNA-binding and function.
CC       {ECO:0000250}.
CC   -!- DISEASE: Hypoparathyroidism, sensorineural deafness, and renal disease
CC       (HDR) [MIM:146255]: A disease characterized by steroid-resistant
CC       nephrosis with progressive renal failure, hypoparathyroidism,
CC       sensorineural deafness, and renal dysplasia.
CC       {ECO:0000269|PubMed:10935639, ECO:0000269|PubMed:11389161,
CC       ECO:0000269|PubMed:26514990}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/107/GATA3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X58072; CAA41102.1; -; mRNA.
DR   EMBL; X55037; CAA38877.1; -; mRNA.
DR   EMBL; X55122; CAA38916.1; -; mRNA.
DR   EMBL; M69106; AAA35870.1; -; mRNA.
DR   EMBL; AY497006; AAR32096.1; -; Genomic_DNA.
DR   EMBL; AL390294; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86367.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86368.1; -; Genomic_DNA.
DR   EMBL; BC003070; AAH03070.1; -; mRNA.
DR   EMBL; BC006793; AAH06793.1; -; mRNA.
DR   CCDS; CCDS31143.1; -. [P23771-2]
DR   CCDS; CCDS7083.1; -. [P23771-1]
DR   PIR; A39794; A39794.
DR   RefSeq; NP_001002295.1; NM_001002295.2. [P23771-2]
DR   RefSeq; NP_002042.1; NM_002051.3. [P23771-1]
DR   RefSeq; XP_005252499.1; XM_005252442.3. [P23771-2]
DR   RefSeq; XP_005252500.1; XM_005252443.6. [P23771-2]
DR   RefSeq; XP_047281000.1; XM_047425044.1. [P23771-1]
DR   RefSeq; XP_047281001.1; XM_047425045.1. [P23771-1]
DR   RefSeq; XP_054221503.1; XM_054365528.1. [P23771-2]
DR   RefSeq; XP_054221504.1; XM_054365529.1. [P23771-2]
DR   RefSeq; XP_054221505.1; XM_054365530.1. [P23771-2]
DR   RefSeq; XP_054221506.1; XM_054365531.1. [P23771-1]
DR   RefSeq; XP_054221507.1; XM_054365532.1. [P23771-1]
DR   PDB; 4HC7; X-ray; 2.65 A; A/B=260-370.
DR   PDB; 4HC9; X-ray; 1.60 A; A=260-370.
DR   PDB; 4HCA; X-ray; 2.80 A; A=260-370.
DR   PDBsum; 4HC7; -.
DR   PDBsum; 4HC9; -.
DR   PDBsum; 4HCA; -.
DR   AlphaFoldDB; P23771; -.
DR   SMR; P23771; -.
DR   BioGRID; 108895; 181.
DR   CORUM; P23771; -.
DR   DIP; DIP-61302N; -.
DR   FunCoup; P23771; 3800.
DR   IntAct; P23771; 178.
DR   MINT; P23771; -.
DR   STRING; 9606.ENSP00000368632; -.
DR   GlyGen; P23771; 9 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; P23771; -.
DR   PhosphoSitePlus; P23771; -.
DR   BioMuta; GATA3; -.
DR   DMDM; 120962; -.
DR   jPOST; P23771; -.
DR   MassIVE; P23771; -.
DR   PaxDb; 9606-ENSP00000368632; -.
DR   PeptideAtlas; P23771; -.
DR   ProteomicsDB; 54162; -. [P23771-1]
DR   ProteomicsDB; 54163; -. [P23771-2]
DR   Antibodypedia; 11113; 1144 antibodies from 49 providers.
DR   DNASU; 2625; -.
DR   Ensembl; ENST00000346208.4; ENSP00000341619.3; ENSG00000107485.18. [P23771-1]
DR   Ensembl; ENST00000379328.9; ENSP00000368632.3; ENSG00000107485.18. [P23771-2]
DR   GeneID; 2625; -.
DR   KEGG; hsa:2625; -.
DR   MANE-Select; ENST00000379328.9; ENSP00000368632.3; NM_001002295.2; NP_001002295.1. [P23771-2]
DR   UCSC; uc001ijz.4; human. [P23771-1]
DR   AGR; HGNC:4172; -.
DR   CTD; 2625; -.
DR   DisGeNET; 2625; -.
DR   GeneCards; GATA3; -.
DR   HGNC; HGNC:4172; GATA3.
DR   HPA; ENSG00000107485; Tissue enhanced (parathyroid gland, skin).
DR   MalaCards; GATA3; -.
DR   MIM; 131320; gene.
DR   MIM; 146255; phenotype.
DR   neXtProt; NX_P23771; -.
DR   OpenTargets; ENSG00000107485; -.
DR   Orphanet; 585936; B-lymphoblastic leukemia/lymphoma with hyperdiploidy.
DR   Orphanet; 2237; Hypoparathyroidism-sensorineural deafness-renal disease syndrome.
DR   PharmGKB; PA28586; -.
DR   VEuPathDB; HostDB:ENSG00000107485; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   GeneTree; ENSGT00940000159247; -.
DR   HOGENOM; CLU_027524_1_0_1; -.
DR   InParanoid; P23771; -.
DR   OMA; ECVKYQV; -.
DR   OrthoDB; 2162994at2759; -.
DR   PAN-GO; P23771; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; P23771; -.
DR   TreeFam; TF315391; -.
DR   PathwayCommons; P23771; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9830364; Formation of the nephric duct.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P23771; -.
DR   SIGNOR; P23771; -.
DR   BioGRID-ORCS; 2625; 76 hits in 1184 CRISPR screens.
DR   CD-CODE; 38EC0B30; Transcriptional condensate.
DR   CD-CODE; 462A97B5; Leucocyte nuclear body.
DR   CD-CODE; ECBAC048; MegaTrans enhancer complex.
DR   ChiTaRS; GATA3; human.
DR   EvolutionaryTrace; P23771; -.
DR   GeneWiki; GATA3; -.
DR   GenomeRNAi; 2625; -.
DR   Pharos; P23771; Tbio.
DR   PRO; PR:P23771; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P23771; protein.
DR   Bgee; ENSG00000107485; Expressed in upper leg skin and 154 other cell types or tissues.
DR   ExpressionAtlas; P23771; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IMP:UniProtKB.
DR   GO; GO:0070888; F:E-box binding; IDA:BHF-UCL.
DR   GO; GO:1990226; F:histone methyltransferase binding; IEA:Ensembl.
DR   GO; GO:0071837; F:HMG box domain binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0005134; F:interleukin-2 receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0001223; F:transcription coactivator binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0001709; P:cell fate determination; ISS:UniProtKB.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IEP:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEP:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0043583; P:ear development; IMP:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IBA:GO_Central.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0002520; P:immune system development; IBA:GO_Central.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0072676; P:lymphocyte migration; IDA:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; ISS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; IEA:Ensembl.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; IDA:UniProtKB.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:2000146; P:negative regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:2000607; P:negative regulation of cell proliferation involved in mesonephros development; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:2000703; P:negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:2000734; P:negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0032689; P:negative regulation of type II interferon production; IEA:Ensembl.
DR   GO; GO:0072179; P:nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0072178; P:nephric duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0071599; P:otic vesicle development; IEA:Ensembl.
DR   GO; GO:0060017; P:parathyroid gland development; IEA:Ensembl.
DR   GO; GO:0035898; P:parathyroid hormone secretion; IEA:Ensembl.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:UniProtKB.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0032736; P:positive regulation of interleukin-13 production; IDA:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0032754; P:positive regulation of interleukin-5 production; IDA:UniProtKB.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IMP:UniProtKB.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; IEA:Ensembl.
DR   GO; GO:2000611; P:positive regulation of thyroid hormone generation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0072107; P:positive regulation of ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0002572; P:pro-T cell differentiation; IEA:Ensembl.
DR   GO; GO:2000683; P:regulation of cellular response to X-ray; IMP:UniProtKB.
DR   GO; GO:0001817; P:regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IBA:GO_Central.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0045622; P:regulation of T-helper cell differentiation; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEP:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; ISS:UniProtKB.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; IDA:MGI.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045064; P:T-helper 2 cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045061; P:thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0031929; P:TOR signaling; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0001806; P:type IV hypersensitivity; IEA:Ensembl.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0072197; P:ureter morphogenesis; IEA:Ensembl.
DR   GO; GO:0060676; P:ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0060065; P:uterus development; ISS:UniProtKB.
DR   GO; GO:0003281; P:ventricular septum development; ISS:UniProtKB.
DR   CDD; cd00202; ZnF_GATA; 2.
DR   DisProt; DP02798; -.
DR   FunFam; 3.30.50.10:FF:000001; GATA transcription factor (GATAd); 1.
DR   FunFam; 3.30.50.10:FF:000032; Transcription factor GATA-3; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 2.
DR   InterPro; IPR016374; TF_GATA-2/3.
DR   InterPro; IPR039355; Transcription_factor_GATA.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071:SF106; TRANS-ACTING T-CELL-SPECIFIC TRANSCRIPTION FACTOR GATA-3; 1.
DR   PANTHER; PTHR10071; TRANSCRIPTION FACTOR GATA FAMILY MEMBER; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PIRSF; PIRSF003027; TF_GATA-1/2/3; 1.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Deafness; Disease variant;
KW   DNA-binding; Immunity; Innate immunity; Metal-binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..443
FT                   /note="Trans-acting T-cell-specific transcription factor
FT                   GATA-3"
FT                   /id="PRO_0000083408"
FT   ZN_FING         263..287
FT                   /note="GATA-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   ZN_FING         317..341
FT                   /note="GATA-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   REGION          1..258
FT                   /note="Interaction with TBX21"
FT                   /evidence="ECO:0000250|UniProtKB:P23772"
FT   REGION          1..29
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          128..180
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          194..216
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          288..316
FT                   /note="Flexible linker"
FT   REGION          361..389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          414..443
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           344..353
FT                   /note="YxKxHxxxRP"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        135..150
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..377
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        414..429
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VAR_SEQ         259
FT                   /note="T -> TE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1871134, ECO:0000303|PubMed:2017177"
FT                   /id="VSP_001598"
FT   VARIANT         242
FT                   /note="G -> S (in dbSNP:rs11567901)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_019202"
FT   VARIANT         274
FT                   /note="W -> R (in HDR; dbSNP:rs104894163)"
FT                   /evidence="ECO:0000269|PubMed:11389161"
FT                   /id="VAR_017818"
FT   VARIANT         298
FT                   /note="R -> Q (in HDR; loss of enhancer activity on PTH
FT                   gene promoter and on GATA responsive element;
FT                   dbSNP:rs2131501118)"
FT                   /evidence="ECO:0000269|PubMed:26514990"
FT                   /id="VAR_075427"
FT   VARIANT         366
FT                   /note="R -> L (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033025"
FT   CONFLICT        11
FT                   /note="V -> L (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102
FT                   /note="A -> V (in Ref. 2; CAA38877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        173
FT                   /note="A -> G (in Ref. 2; CAA38877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        219
FT                   /note="I -> Y (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225..226
FT                   /note="YV -> TC (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285..286
FT                   /note="NA -> RR (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        425
FT                   /note="P -> A (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        441
FT                   /note="A -> G (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   TURN            264..266
FT                   /evidence="ECO:0007829|PDB:4HC9"
FT   HELIX           285..294
FT                   /evidence="ECO:0007829|PDB:4HC9"
FT   STRAND          307..313
FT                   /evidence="ECO:0007829|PDB:4HC7"
FT   TURN            318..320
FT                   /evidence="ECO:0007829|PDB:4HC9"
FT   HELIX           339..348
FT                   /evidence="ECO:0007829|PDB:4HC9"
FT   HELIX           354..356
FT                   /evidence="ECO:0007829|PDB:4HC9"
SQ   SEQUENCE   443 AA;  47916 MW;  F24C58681E1D02A5 CRC64;
     MEVTADQPRW VSHHHPAVLN GQHPDTHHPG LSHSYMDAAQ YPLPEEVDVL FNIDGQGNHV
     PPYYGNSVRA TVQRYPPTHH GSQVCRPPLL HGSLPWLDGG KALGSHHTAS PWNLSPFSKT
     SIHHGSPGPL SVYPPASSSS LSGGHASPHL FTFPPTPPKD VSPDPSLSTP GSAGSARQDE
     KECLKYQVPL PDSMKLESSH SRGSMTALGG ASSSTHHPIT TYPPYVPEYS SGLFPPSSLL
     GGSPTGFGCK SRPKARSSTG RECVNCGATS TPLWRRDGTG HYLCNACGLY HKMNGQNRPL
     IKPKRRLSAA RRAGTSCANC QTTTTTLWRR NANGDPVCNA CGLYYKLHNI NRPLTMKKEG
     IQTRNRKMSS KSKKCKKVHD SLEDFPKNSS FNPAALSRHM SSLSHISPFS HSSHMLTTPT
     PMHPPSSLSF GPHHPSSMVT AMG
//
